For the current quarter Argos Therapeutics (NASDAQ:ARGS) has average revenue estimates of $50 Million, a total number of 1 analysts provided estimations over revenues. Relative volume is the comparison of current volume to average volume for the same time of day, and it's displayed as a ratio. The company has market cap of $11.85 million.
Shares of Argos Therapeutics (NASDAQ:ARGS) has a market capitalization of $15.47 Million and its number of outstanding shares are 94.9 Million. The rating was maintained by Needham with "Buy" on Tuesday, November 17. The New York-based Virtu Llc has invested 0% in Argos Therapeutics, Inc. The firm acquired 665,831 shares of the biopharmaceutical company's stock, valued at approximately $120,000.
Right now, ARGS's beta is 1.41. (AFGE) has $9.45B valuation. This will give analytical advantage to a shorter-term trader since it pursues the price more intimately, and consequently produces less "lag" as comparison to the longer-term moving average. Chipotle Mexican Grill, Inc. (NYSE:AFGE) has declined 0.59% since January 19, 2017 and is downtrending.
Argos Therapeutics, Inc (Argos) is an immuno-oncology company. During previous trade 2.65 Million shares of Argos Therapeutics (NASDAQ:ARGS) exchanged hands whereas on average nearly 4.74 Million shares has been traded. The Company's Arcelis technology platform utilizes biological components from a patient's own cancer cells or virus to generate individualized immunotherapies. It now has negative earnings. At the moment several experts are conducting its evaluation in the pivotal ADAPT Phase 3 clinical trial which is specifically targeted towards the treatment of metastatic renal cell carcinoma (mRCC). It tells an investor how quickly a company is increasing its revenues. Its up 0.09, from 0.54 in 2017Q2. Argos Therapeutics, Inc. (NASDAQ:ARGS) has a 20-Day average volume of 4.68 Million. Argos Therapeutics (NASDAQ:ARGS)'s price to earnings ratio stood at 0. Northern Trust holds 43,244 shares. Also, Argos Therapeutics, Inc. Wasatch Advisors Inc. purchased a new position in Argos Therapeutics Inc (NASDAQ:ARGS) in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. (NASDAQ:ARGS) advice adding it to buy candidate list. Bnp Paribas Arbitrage accumulated 4 shares or 0% of the stock.
Are Argos Therapeutics, Inc. That suggests something of the likelihood of a short squeeze in shares of ARGS. Moreover, Vanguard Grp has 0% invested in Argos Therapeutics, Inc. (NASDAQ:ARGS)'s near-term growth potential.
More news for Argos Therapeutics, Inc.
Taking a broader look brokerage firms' analysts on the street with an expectant view have Argos Therapeutics (NASDAQ:ARGS) high price target of $0.75 and with a conservative view have low price target of $0.75. Barclays Pcl holds 100 shares.
The stock decreased 12.84% or $0.0206 during the last trading session, reaching $0.1398. Whereas, in last 21 trading days (one month) was -2.71% and moved down in last 63 trading days (quarter) of -17.71%. 1 is equivalent to a buy rating, 3 a hold rating, and 5 a sell rating. It has underperformed by 109.27% the S&P500. This is according to a simplified 1 to 5 scale where 1 represents a Strong Buy and 5 a Strong Sell. Chipotle Mexican Grill Inc. had 211 analyst reports since July 22, 2015 according to SRatingsIntel. A high degree of volume indicates a lot of interest in a stock. The rating was maintained by Jefferies with "Sell" on Wednesday, July 19.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter. The rating was downgraded by Wells Fargo to "Market Perform" on Wednesday, July 19. The firm has "Neutral" rating by Wedbush given on Thursday, January 5. The firm has "Underperform" rating by Cowen & Co given on Friday, September 8. Netflix Inc (NASDAQ:NFLX) was reduced too.
SC to examine Justice Loya's death records
The top court also asked all parties to catalogue documents in Loya's matter, which have not been filed so far and submit them. The CJI-led bench started hearing the pleas following the recusal last week by another SC bench headed by Justice Arun Mishra.